Background: The biology of bone repair and healing is interesting and a huge number of studies have been done in this aspect with the potential technologies for enhancing fracture-healing. Teriparatide an anabolic agent a recombinant parathyroid hormone preparation that activates osteoblastic bone formation has been used in the treatment of postmenopausal osteoporosis. It has also been reported to be effective in accelerating the rate of fracture healing. The conclusion that PTH as an effective anabolic therapy for the enhancement of bone repair after fracture has been studied in animals and very few case studies. This prospective study was conducted to determine and establish the role of recombinant teriparatide in fracture healing in delayed union fractures, osteoporotic fractures, periprosthetic fractures.
Introduction
Bone healing after a fracture is a special form of wound-healing. The bone regenerates rapidly and heals without a scar. The three stages of bone repair are: inflammatory (haematoma formation with induction of inflammation), reparative (callus formation with stabilization), and remodeling (balancing and returning to its near normal structure). When a bone is injured and sustains a fracture there is a release of inflammatory cells which cause the release of many variety of substances which include TNFa, growth factors,VEGF,IL-3/6, fibronectin, histamine, fibroblasts, endothelial cells, osteoblasts and many more which all in conjecture help fill the void at the fracture site with inflamatory tissue. The second stage which is the reparative phase begins at about 2 weeks and involves a periosteal response with new blood vessel formation for the new bone and cells to survive and nourishment. This leads to the stabilization of the fracture site with the formation of connective tissue and soft callus, which is gradually turned into immature woven bone via intramembranous or endochondral bone formation. The final stage is the remodeling phase where the woven bone callus is eventually replaced by lamellar bone. In many cases the fracture healing is by endochondral bone formation pathway, but an intervention with a rigid fixation can lead to a primary cortical repair. In course of time the fracture undergoes osteoclast-mediated remodeling which leads to the restoration of its original geometry and structural integrity. Despite this inherent complex and co-ordinated nature of the repair process, many patients still require a longer duration of time before a fracture is completely healed and returns to its original indentity. This has promoted keen interests in the biology and its modifications in treatments that could stimulate and increase the rate of fracture healing and repair, providing decreased morbidity and an early return to an active lifestyle and work. This fracture healing is assisted by many biological agents, one of them being the parathyroid hormone. Biochemically parathyroid hormone (PTH) is a protein polypeptide made up of amino-acids. It is a key regulator in the calcium and phosphate metabolism. The principal effect of PTH in the metabolism and maintaining the bone mineral equilibrium are to increase serum calcium levels which is by increasing the gastrointestinal calcium absorption, increases renal calcium and phosphate reabsorption, activates osteoclasts to release calcium from the skeleton in response to hypocalcemia, and play a role in the regulation of vitamin-D metabolism 1 . The teriparatide hormone is a synthetic molecule which has the first 34 fragments of the biological human parathyroid hormone and hence retains most of the biochemical activities of the human PTH [3] . When teriparatide is intermittently administred it has similar anabolic effects of PTH that stimulate bone formation and activate bone remodeling [2, 4] , enhancing the micro-architecture of the trabecular and cortical bone [5] . Some of the earlier studies and papers reported that teriparatide also increased bone mineral density and lowered the risk of vertebral and non-vertebral fractures [6, 7] . Teriparatide was the only anabolic molecule used in osteoporosis which had a approval by the Food and Drug Administration [8] .
The electron microscpic study of the structure of Pararthyroid hormone have proved that the N-terminal portion of the PTH molecule with the first 34 amino acids called PTH(1-34) is the main structure responsible for most of its biological activity [9, 10] . The teriparatide molecule has a mass of 4117.8 daltons [11] . It is synthesized using a genetically altered strain of Escherichia coli and is manufactured in a solution form for subcutaneous injection [11] . Teriparatide when administed intermittently has the ability to stimulate bone formation hence it seems reliable to consider that teriparatide might improve and enhance the bone quality and hence aid in fracture healing [12] [13] [14] [15] . Some of the new studies about fragility fracture cases have been benefited with the administration of teriparatide [16, 17] . An increasing number of clinical studies have shown that the administration of PTH (1-34) is beneficial in the treatment of preventing fragility fractures in patients with osteoporosis, these studies have shown that even after discontinuing the treatment the positive effects are seen for many years [19] [20] [21] [22] . The continued growth and positive effects have led to the development of particular PTH analogs (1-31, 1-34, or 1-84) and similar compounds of Pararthyroid hormone in the region of dual coupled remodeling, and hence drastically providing increased patient benefit and compliance. Teriparatide increases cortical as well as trabecular bone density by increasing bone formation and also promotes resorption of the bone by osteoclasts [23] [24] [25] [26] [27] . The biochemical action of Teriparatide is via the PTH-1 receptors which is present on the bone forming osteoblasts and bone marrow stromal cells to induce osteoblastic bone formation and increased mineralization [25] . As a result of this increased mineralisation there is reduction in the fragility fractures which is equal to or over, those seen by the use of antiresorptive agents [15] . The increase in the bone mineral density induced by teriparatide is considerable which ranges from 10% to 15% in 2 to 3 years in most of the studies [28] [29] [30] [31] [32] [33] .
These studies most of which have been single case reports or animal studies and hence there is a controversy in the matter of the use of teriparatide in fracture preventing and healing. A few of the randomized controlled trials (RCTs) have shown that there was no significant difference between the group treated with teriparatide and the group treated with placebo [34, 35] . Considering all these factors the evidence of light on this subject of matter is very minimal and hence the action of teriparatide in fragility fracture healing remains an enigma and is controversial. In view of this we have designed a study to demonstrate and know the use and efficacy of teriparatide in enhancing fracture healing in different fracture groups that includes delayed union, osteoporotic, periprosthetic fractures.
Materials and methods
The study was done on 20 patients with fractures selected on the basis of inclusion and exclusion criteria at Shaswat hospital, Pune during the period of September 2011 to September 2015. This study included both male and female patients. Inclusion criteria were patients with 1) age more than 25 years 2) delayed union 3) periprosthetic fractures 4) osteoporotic fractures. Exclusion criteria were 1) Age less than 25 years 2) Compound fractures 3) Associated significant systemic comorbid illnesss 4) History of tumor or chemotherapy, bone metastases, metabolic bone disease, rheumatoid arthritis, chronic renal failure 5) pregnant and lactating women. The patients which satisfied the inclusion criteria were selected and on arrival at the hospital detailed history and clinical examination was done. Routine blood investigations like CBC, ESR, RFT, RBS were done. Concomitant co morbidities were addressed and specific treatment given. Xrays were taken before starting the injection in at least two views preferably AP and Lateral views. Patients were explained in detail about the injection its nature of action, the course of treatment and its side effects. Once the patients agreed to the treatment, informed valid written consent was taken. All patients were administered 20ug of teriparatide injections daily, first 2-3 injections were given under guidance and later patient advised to continue the same daily at home. Injection were given subcutaneously in the lower abdomen or thigh through a preloaded syringe which contain drug for 28 days. Injection can be taken any time in a day but patients were advised to take it usually at a same time daily. Any left over drug after 28 days discarded with the syringe. syringe kept in refrigerator at 2 0 to 8 0 C and never kept in freezer. Patients were informed to report to the hospital in case of any complications like nausea, vomiting, dizziness, cramps, weakness. Injections were started immediately in periprosthetic and osteoporotic fractures and in delayed union once the diagnosis was established. Injections were given for 2-4months depending on type of fracture and radiological evidence of union. Radiographs were taken every 4 weeks to see for callus and fracture union. Patients were enquired about drug compliance, adverse effect and complications associated with daily injections. The primary endpoint of fracture healing was taken as the time of cortical bridging in three of four cortices. all patients were given daily calcium supplement of 1000 mg and vitamin D3 60,000 IU weekly. NSAIDs was given for pain relief. splints like slab, immobilisers, brace were given specific to a fracture. Isovolumetric exercises usually started immediately. isotonic and weight bearing started when radiological callus seen on radiogram minimum after 4 weeks. (Table 11 ). The mean age of the patients were 60.7 years (delayed union 48.42 years, osteoporotic 76 years, periprosthetic group 57.16 years) and ranged from 40-83 years. A total of 10 males (50%) and 10 females (50%) were involved. Fracturesinvolving various anatomical sites were evaluated. Fracture sites included humerus, radius, wrist, femur, tibia, and ankle. A total of 20 patients had dailyinjection of subcutaneous teriparatide. All of the patientswere administered 20μg of teriparatide. The signs of healing were seen in all the patients at 3-4 weeks. The mean dosage of teriparatide injection time was 12.6 weeks. The minimum duration was 10 and themaximum duration was 16 weeks. We analysed the efficacy of teriparatide via radiological outcome. Radiological findings involved the use of Xrays to assess for callus formation, bony bridging, reduction of fracture line and complete bony union. The mean time to bony bridging after starting PTH (1-34) varied widely across different fracture groups. (table 2) For delayed union fractures, administration of teriparatide was associated with a mean time to bony bridging of 12 weeks. For periprosthetic fractures the average healing time was 12.6 weeks.13.2 weeks for osteoporotic fracture group. A total of 6 patients experienced mild side effect from teriparatide administration. 1 patients complained of dizziness while 3 patients reported mild side effects such as nausea, vomiting and 2 patients reported to have leg cramps. No other side effects were noted from the studies involving teriparatide administration. none of the side effects were that significant to cause discontinuation of teriparatide. 
Results
A total of 20 patients with 20 fractures treated were evaluated in this study
Discussion
Fracture healing is considered as a very complex process that involves the coupled effect of resorption and formation. For elderly osteoporotic subjects, the bone is ductile, weak and undergoes plastic deformation well before fragility breaks can occur. The main action of the synthetic molecule teriparatide is to enhance and stimulate bone formation which is by increasing the osteoblastic activity. It does not stimulate bone resorption. This is known as the "anabolic window." There a number of mechanisms for teriparatide to facilitate fracture healing, which include promoting proliferation and differentiation of mesenchymal stem cell, chondroprogenitors and osteoprogenitors, chondrocyte maturation, production of bone matrix proteins, and formation of osteoclasts. In the course of fracture healing, it can promote callus formation by incorporating and stimulating the proliferation and differentiation of osteoprogenitors and chondroprogenitors [36, 37] . It also promotes the early callus formation and callus remodeling by stimulating matrix proteins for the bones and formation of osteoclasts [37] . TheWnt/ -catenin signaling pathway which regulates the type II and X collagen involved in determining the size of the callus is also promoted and enhanced by the administration of teriparatide [38] . The effect of Teriparatide on fracture healing has been shown to be beneficial. Some of the literature and recent papers on the effect of teriparatide in primary union, delayed and nonunion have resulted in enhancement in the time to clinical and radiological union. 1 weeks, n = 34) . Surprisingly, the study acknowledges a lack of dose response relationship with intermittent administrationof PTH 1-34. The treatment group (n = 34) thatreceived teriparatide 40 μg day-1 showed shorterhealing time compared to the control group. Youngwoo Kim et al. studied effect of teriparatide in femoral shaft fractures showed that the callus formation after teriparatide therapy was approximately 2 weeks more early than normal healing. Moreover, this callus formation progressed for 8 weeks and led to healing of the fracture. In delayed unions the trearment of choice is bone grafting but this procedure is not without complications of the fracture site as well the donor site morbidity. In our study we see that union was achieved in such fractures with only the use of teriparatide. Teriparatide also is useful in the management of hypophosphatemic patients. These patients who have defective bone mineralization are benefitted by treatment with teriparatide. The safety profile of Teriparatide continues to be excellent with only 8 of patients experiencing mild side effects ranging from nausea, vomiting and headache. In the study by Peichlet al. (2011) no adverse events or death were recorded among the 21 patients who took PTH 1-84 for 24months (Peichl et al., 2011) . The long-term safety profile of teriparatide is however still unknown. The anabolic effects of teriparatide when given long-term and in supra-physiological doses were associated with an increased risk of osteosarcomas in Fisher rats (Vahle etal., 2002) . This risk is negated by the use of smaller doses in humans and is somewhat comparable to the general population risk, where only 1 case of osteosarcoma has been reported (Harper et al., 2007) among more than 250,000-300,000 patients treated with teriparatide worldwide (Solomon et al., 2009 ). Due to this risk profile of the hormone its use is cautioned in patients with significant history of primary or metastatic bone tumours, Paget's disease, unexplained high levels of ALP, history of radiation therapy involving the bones or metabolic bone disease excluding osteoporosis, pregnancy and breast feeding (Guide et al., 2002) . Some of the other side effects of teriparatide include dizziness, constipation, lethargy, muscle weakness and cramping in the legs which is due to raised serum calcium levels. The local side effects at the site of injection include erythema, swelling, itch and pain. Teriparatide also can raise the serum uric acid levels and precaution has to be taken in patients with renal impairment. We acknowledge several limitations in our study. Considering that teriparatide has not commonly been used in fracture healing and its recent application for the same. The small sample size and the lack of control group were the other limitations.
Conclusion
Teriparatide is a relatively safe drug with minimal adverse effects. Economical compared to other options of fracture healing like bone grafting, second surgery. Less invasive, more cost effective and better patient compliance. Enhances fracture healing by stimulating exuberant callus formation and has constant positive anabolic effect throughout the period of remodeling in fracture-healing. Teriparatide is an effective therapy to enhance the bone material density and prevent fragility fractures in elderly patients. However, studies across this field are not much and some more clinical studies are needed to determine the usefulness of teriparatide and the clinical indications for the use of teriparatide in the treatment of fracture healing.
